As an active inhibitor of SGLT2, canagliflozin, a novel oral hypoglycemic agent, has been approved as an adjunct to diet and exercise to improve glycemic control in T2DM patients in several countries [6,7,8]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.